K+ channel opening: A new drug principle in cardiovascular medicine

Heart

Volumn 76, Issue 2, 1996, Pages 109-116

  Nielsen Kudsk, Jens Erik ^a   Boesgaard, Søren ^a   Aldershvile, Jan ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

APRIKALIM; BENZOPYRAN DERIVATIVE; BENZOTHIADIAZINE DERIVATIVE; BIMAKALIM; CROMAKALIM; DIAZOXIDE; GUANIDINE DERIVATIVE; MINOXIDIL SULFATE; N (4 CHLOROPHENYL) N' CYANO N'' (6 CYANO 3,4 DIHYDRO 3 HYDROXY 2,2 DIMETHYL 2H 1 BENZOPYRAN 4 YL)GUANIDINE; N CYANO N' (2 NITROXYETHYL) 3 PYRIDINECARBOXIMIDAMIDE; NICORANDIL; PINACIDIL; POTASSIUM CHANNEL; POTASSIUM CHANNEL STIMULATING AGENT; PYRIMIDINE DERIVATIVE; RILMAKALIM;

ANGINA PECTORIS; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG MECHANISM; HEART FAILURE; HEART MUSCLE FIBER MEMBRANE POTENTIAL; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LUNG CIRCULATION; PRIORITY JOURNAL; REVIEW;

EID: 0029781940     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.76.2.109     Document Type: Review

References (51)

1. Katz AM. Cardiac ion channels. N Engl J Med 1993;328: 1244-51.
2. Quast U. Potassium channel openers: pharmacological and clinical aspects. Fundam Clin Pharmacol 1992,6:279-93.
3. Edwards G, Weston AH. Pharmacology of the potassium channel openers. Cardiovasc Drugs Ther 1995,9:185-93.
4. Edwards G, Duty S, Trezise DJ, Weston AH. Effects of potassium channel modulators on the cardiovascular system. In:. Weston AH, Hamilton TC, eds. Potassium channel modulators. Oxford: Blackwell Scientific Publications, 1992;369-421.
5. + Channels in cardiovascular medicine. Paris: Springer-Verlag, 1993;193-223.
6. + Channels in cardiovascular medicine. Paris: Springer-Verlag, 1993; 225-44.
7. Cavero I, Djellas Y, Guillon JM. Ischemic myocardial cell protection conferred by the opening of ATP-sensitive potassium channels. Cardiovasc Drugs Ther 1995;9: 245-55.
8. Nelson MT, Quayle JM. Physiological roles and properties of potassium channels in arterial smooth muscle. Am J Physiol 1995;268:C799-C822.
9. + channels. Am J Physiol 1995;268:C535-C56.
10. + channels in cardiac muscle. Nature 1983;305:147-8.
11. Coetzee WA. ATP-sensitive potassium channels and myocardial ischaemia: why do they open? Cardiovasc Drugs Ther 1992;6:201-8.
12. + channel openers and 'natural' cardioprotection. Trends Pharmacol Sci 1992;13:269-72.
13. ATP channels in vascular smooth muscle. Cardiovase Res 1994;28:797-804.
14. Daut J, Maier Rudolph W, von Beckerath N, Mehrke G, Gunther K, Goedel-Meiner L. Hypoxic dilation of coronary arteries is mediated by ATP-sensitive potassium channels. Science 1990;247:1341-4.
15. 1 receptors by G proteins in rat ventricular myocytes. Am J Physiol 1990; 259:H820-H6.
16. Merkel IA, Lappe RW, Rivera LM, Cox BF, Perrone MH. Demonstration of vasorelaxant activity with an A -selective adenosine agonist in porcine coronary artery: involvement of potassium channels. J Pharmacol Exp Ther 1992,260:437-43.
17. Bolotina VM, Najihi S, Palacino JJ, Pagano PJ, Cohen RA. Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature 1994; 368:850-3.
18. Furukawa K, Itoh T, Kajiwara M, Kitamura K, Suzuki H, Ito Y, et al. Vasodilating actions of 2-nicotinamidoethyl nitrate on porcine and guinea-pig coronary arteries. J Pharmacol Exp Ther 1981;218:248-59.
19. + channel in insulin-secreting cells. J Biol Chem 1987;262:15840-4.
20. Quast U, Guillon JM, Cavero I. Cellular pharmacolog of potassium channel openers in vascular smooth muscle. Cardiovasc Res 1994;28:805-10.
21. Barnes PJ, Liu SJ. Regulation of pulmonary vascular tone. Pharmacol Rev 1995;47:87-131.
22. Post JM, Hume JR, Archer SL, Weir EK. Direct role for potassium channel inhibition in hypoxic pulmonary vasoconstriction. Am J Physiol 1992;262:C882-C90.
23. + channels in cardiovascular medicine. Paris: Springer-Verlag, 1993;141-58.
24. Nielsen-Kudsk JE, Bang L. Effects of pinacidil and other cyanoguanidine derivatives on guinea-pig isolated trachea, aorta and pulmonary artery. Eur J Pharmacol 1991; 201:97-102.
25. Thomas P, Dixon MS, Winterton SJ, Sheridan DJ. Acute haemodynamic effects of cromakalim in patients with angina pectoris. Br J Clin Pharmacol 1990;29:325-31.
26. Mellemkjaer S, Nielsen-Kudsk JE. Glibenclamide inhibits hypoxic relaxation of isolated porcine coronary arteries under conditions of impaired glycolysis. Eur J Pharmacol 1994;270:307-12.
27. Aversano T, Ouyang P, Silverman H. Blockade of the ATP-sensitive potassium channel modulates reactive hyperemia in the canine coronary circulation. Circ Res 1991;69:618-22.
28. Komaru T, Lamping KG, Eastham CL, Dellsperger KC. Role of ATP-sensitive potassium channels in coronary microvascular autoregulatory responses. Circ Res 1991; 69:1146-51
29. Imamura Y, Tomoike H, Narishige T, Takahashi T, Kasuya H, Takeshita A. Glibenclamide decreases basal coronary blood flow in anesthetized dogs. Am J Physiol 1992;263:H399-H404.
30. Ghaleh B, Dubois Rande JL, Hittinger L, Giudicelli JF, Berdeaux A. Comparisons of the effects of nicorandil, pinacidil, nicardipine and nitroglycerin on coronary vessels in the conscious dog: role of the endothelium. Br J Pharmacol 1995;114:496-502.
31. + channel opener aprikalim (RP 52891) reduces experimental infarct size in dogs in the absence of hemodynamic changes. J Pharmacol Exp Ther 1991;259: 961-7.
32. Grover GJ. Protective effects of ATP-sensitive potassium-channel openers in experimental myocardial ischemia. J Cardiovasc Pharmacol 1994;24 suppl 4:S18-S27.
33. Auchampach JA, Maruyama M, Cavero I, Gross GJ. Pharmacological evidence for a role of ATP-dependent potassium channels in myocardial stunning. Circulation 1992;86:311-9.
34. Grover GJ, McCullough JR, D'Alonzo AJ, Sargent CA, Atwal KS. Cardioprotective profile of the cardiacselective ATP-sensitive potassium channel opener BMS-180448. J Cardiovasc Pharmacol 1995;25:40-50.
35. Mellemkjaer S, Nielsen-Kudsk JF. Effects of levcromakalim and glibenclamide on paced guinea-pig atrial strips exposed to hypoxia. Eur J Pharmacol 1995;277: 516.
36. ATP channel opener bimakalim on coronary blood flow, monophasic action potential duration, and infarct size in dogs. Circulation 1994;89:1769-75.
37. ATP opener cromakalim is not correlated with ischemic myocardial action potential duration. J Cardiovasc Pharcacol 1995;26:145-52.
38. Gross GJ. ATP-sensitive potassium channels and myocardial preconditioning. Basic Res Cardiol 1995;90:85-8.
39. Gross GJ, Auchampach JA. Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. Circ Res 1992;70:223-33.
40. Yao Z, Gross GJ. Activation of ATP-sensitive potassium channels lowers threshold for ischemic preconditioning in dogs. Am J Physiol 1994;267:H1888-H94.
41. + channel blocker. Circulation 1994; 90:700-5.
42. 1-receptors. Circulation 1992;86:1310-6.
43. Wilde AA, Janse MJ. Electrophysiological effects of ATP sensitive potassium channel modulation: implications for arrhythmogenesis. Cardiovasc Res 1994;28:16-24.
44. Black SC, Lucchesi BR. Potassium channel openers are likely to be proarrhythmic in the diseased human heart. Cardiovasc Res 1994;28:923-4.
45. D'Alonzo AJ, Grover GJ. Potassium channel openers are unlikely to be proarrhythmic in the diseased human heart. Cardiovasc Res 1994;28:924-5.
46. Friedel HA, Brogden RN. Pinacidil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension. Drugs 1990;39:929-67.
47. Frampton J, Buckley MM, Fitton A, Nicorandil. A review of its pharmacology and therapeutic efficacy in angina pectoris. Drugs 1992;44:625-55.
48. Knight C, Purcell H, Fox K. Potassium channel openers: clinical applications in ischemic heart disease - overview of clinical efficacy of nicorandil. Cardiovasc Drugs Ther 1995;9:229-36.
49. Cook NS, Chapman ID. Therapeutic potential of potassium channel openers in peripheral vascular disease and asthma. Cardiovasc Drugs Ther 1993;7 suppl 3:555-63.
50. University Group Diabetes Program. A story of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970;19:789-830.
51. Smits P, Thien T. Cardiovascular effects of sulphonylurea derivatives. Implications for the treatment of NIDDM? Diabetologia 1995;38:116-21.